Literature DB >> 17363721

Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas.

Jonathan Golledge1, Simone Mangan, Paula Clancy.   

Abstract

BACKGROUND AND
PURPOSE: Severely stenotic, symptomatic carotid atheromas are associated with a high risk of stroke in the short term. Although carotid endarterectomy is effective in reducing this stroke risk, it is frequently not applied within the time window for significant benefit. We investigated the effect of peroxisome proliferator-activated receptor (PPAR) -alpha and -gamma ligands in acutely modifying tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in unstable carotid atheromas.
METHODS: During a 3-year period, 64 patients who had experienced a transient ischemic attack or stroke with good recovery within 6 weeks before surgery and 12 asymptomatic patients with a >70% carotid stenosis were recruited. The expression of PPAR-alpha and -gamma was investigated in endarterectomy samples. The effects of the PPAR-alpha and -gamma ligands fenofibrate and rosiglitazone were investigated in cell culture experiments. Targeted biopsy specimens from endarterectomy samples (n=48) were incubated with medication for 4 days. TF and TFPI were assessed by immunohistochemistry, Western blot analysis, flow cytometry, and activity assays.
RESULTS: PPAR-gamma1 but not -alpha was downregulated in atheromas removed from patients with recent symptoms and no evidence of diabetes. Fenofibrate but not rosiglitazone impaired the induction of TF in human endothelial cells and reduced resting levels of TF activity in vascular smooth muscle cells. Rosiglitazone but not fenofibrate increased TFPI secretion from human endothelial cells. Both fenofibrate (100+/-18.7% to 56.6+/-8.8%, P=0.005; 0.2664+/-0.0696 to 0.1771+/-0.0310, P=0.02) and rosiglitazone (100+/-22% to 88.3+/-20%, P=0.02; 0.3113+/-0.0729 to 0.2287+/-0.0415, P=0.04) reduced TF expression and activity, respectively, in atheroma biopsy specimens. A low expression of TFPI was found in atheroma biopsy specimens with little evidence of TFPI activity.
CONCLUSIONS: This study suggests that both PPAR-alpha and -gamma ligands have beneficial effects in acutely reducing TF in unstable carotid atheromas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363721     DOI: 10.1161/STROKEAHA.106.474791

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  10 in total

1.  Role of homocysteine in aortic calcification and osteogenic cell differentiation.

Authors:  Ann Van Campenhout; Corey S Moran; Adam Parr; Paula Clancy; Catherine Rush; Hieronim Jakubowski; Jonathan Golledge
Journal:  Atherosclerosis       Date:  2008-05-28       Impact factor: 5.162

Review 2.  PPARgamma and its ligands: therapeutic implications in cardiovascular disease.

Authors:  Luis Villacorta; Francisco J Schopfer; Jifeng Zhang; Bruce A Freeman; Y Eugene Chen
Journal:  Clin Sci (Lond)       Date:  2009-02       Impact factor: 6.124

3.  Modulation of endothelial cell thrombomodulin by PPAR ligands--variation according to environment.

Authors:  Simone Mangan; Paula Clancy; Jonathan Golledge
Journal:  Thromb Res       Date:  2007-09-14       Impact factor: 3.944

4.  Correlation of Peroxisome Proliferator-Activated Receptor-gamma (PPAR-gamma) and Retinoid X Receptor-alpha (RXR-alpha) expression with clinical risk factors in patients with advanced carotid atherosclerosis.

Authors:  Constantinos Giaginis; Christos Klonaris; Athanassios Katsargyris; Gregorios Kouraklis; Chara Spiliopoulou; Stamatios Theocharis
Journal:  Med Sci Monit       Date:  2011-07

5.  Association of single nucleotide polymorphism rs2076185 in chromosome 6P24.1 with premature coronary artery diseases in Chinese Han population.

Authors:  Xin Liu; Min Zhang; Hong-Wei Shan; Xian-Tao Song; Shu-Zheng Lyu
Journal:  J Geriatr Cardiol       Date:  2016-02       Impact factor: 3.327

6.  Peroxisome Proliferator-Activated Receptor γ Induces the Expression of Tissue Factor Pathway Inhibitor-1 (TFPI-1) in Human Macrophages.

Authors:  G Chinetti-Gbaguidi; C Copin; B Derudas; N Marx; J Eechkoute; B Staels
Journal:  PPAR Res       Date:  2016-12-27       Impact factor: 4.964

7.  Transcriptomic Analysis of Gonadal Adipose Tissue in Male Mice Exposed Perinatally to 2,2',4,4'-Tetrabromodiphenyl Ether (BDE-47).

Authors:  Aser Abrha; Alexander Suvorov
Journal:  Toxics       Date:  2018-03-29

8.  The Role of PPARs in the Endothelium: Implications for Cancer Therapy.

Authors:  David Bishop-Bailey; Karen E Swales
Journal:  PPAR Res       Date:  2008-11-24       Impact factor: 4.964

9.  Use of rosiglitazone before and after vascular injury in hypercholesterolemic rabbits: Assessment of neointimal formation.

Authors:  Alexandre Alessi; Olímpio Ribeiro França Neto; Paulo Roberto Slud Brofman; Camila Prim; Lucia Noronha; Ruy Fernando Kuenzer Caetano Silva; Liz Andréa Villela Baroncini; Dalton Bertolim Précoma
Journal:  Thromb J       Date:  2008-08-27

10.  Interference With Coagulation Cascade as a Novel Approach to Counteract Cisplatin-Induced Acute Tubular Necrosis; an Experimental Study in Rats.

Authors:  Mohamed G Ewees; Basim A S Messiha; Ali A Abo-Saif; Asmaa M A Bayoumi; Mohamed S Abdel-Bakky
Journal:  Front Pharmacol       Date:  2018-10-11       Impact factor: 5.810

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.